Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Finding aid

Bibliography — page 4

124 bibliographic records. Each lists every Institute document that cites it.

Records

124 documents · page 4 of 4

Table 1. Bibliographic records on this page.

TitleFirst authorSourceYearTypeCited by
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone…Prakash ABioDrugs1999Journal article12
Ipamorelin, the first selective growth hormone secretagogueRaun KEuropean Journal of Endocrinology1998Journal article4
Bias in meta-analysis detected by a simple, graphical testEgger MBMJ1997Journal article0
Rational design of stable lyophilized protein formulations: some practical adviceCarpenter JFPharmaceutical Research1997Journal article11

page 4 of 4

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.